{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:08:07Z","timestamp":1784592487618,"version":"3.55.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":56,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Red blood cell (RBC) transfusion may be lifesaving, however transfusion-transmitted infections (TTI) and transfusion-associated graft-versus-host disease (TA-GVHD) still pose a threat despite current donor selection and testing requirements. Amustaline (S-303)\/glutathione (GSH) pathogen reduction (PR) is designed to inactivate infectious microbes and leukocytes in RBCs. The RedeS study evaluates the safety and efficacy of amustaline\/GSH PR-RBCs compared to conventional RBCs in a broad spectrum of patients requiring acute and\/or repeated RBC transfusion support.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>RedeS is a Phase 3, prospective, multi-center, randomized, double-blind, active-controlled, parallel-design study, with a 6-month extension option to evaluate patients requiring repeated transfusions including red cell exchange (RCE). Eligible subjects will be stratified according to site, baseline bleeding status and participation in the extension period. The study arms include a transfusion period of 28-days for anemia with any bleeding or non-bleeding patients or a 28-day\u2009+\u20096-month extension for non-bleeding patients with chronic anemia requiring repeated simple transfusions, or for patients with sickle cell disease (SCD) expected to receive three RCE procedures.<\/jats:p>\n                    <jats:p>The study will seek to enroll 600\u2013800 subjects in the overall safety analysis, including\u2009~\u2009140 repeatedly-transfused subjects in the 6-month extension including up to 30 subjects receiving three RCE procedures. The primary safety endpoints are the proportion of patients with any treatment-emergent adverse events (TEAEs) related to study RBC transfusion through 28 days after the last study transfusion, and the proportion of patients with treatment-emergent antibodies with confirmed specificity to PR-RBCs. The primary efficacy endpoint is the hemoglobin (Hb) increment in subjects who are non-bleeding at baseline, adjusted for the grams of Hb transfused and averaged over multiple transfusions. With 352 evaluable transfused non-bleeding subjects (176 per treatment group) from either arm, the study will have 80% power to demonstrate non-inferiority, defined as a Hb increment treatment difference of no more than 15% of the Control group mean, assuming a Control arm coefficient of variation of 50%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>RedeS will characterize the safety of amustaline\/GSH PR-RBCs and is designed to demonstrate the non-inferiority of PR-RBCs to conventional RBCs with respect to Hb increment, a common pragmatic clinical assessment of RBC transfusion effectiveness.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      A Randomized, Double-Blind, Controlled, Parallel Group Study with the INTERCEPT Blood System for red blood cells in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections (RedeS Study). ClinicalTrials.gov ID NCT03037164. Registered on 27 January 2017 at\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03037164\" ext-link-type=\"uri\">https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03037164<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13063-026-09808-y","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:45:07Z","timestamp":1779756307000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A randomized, double-blind, controlled, parallel group study with amustaline\/glutathione pathogen reduced red blood cells in regions at potential risk for Zika virus transfusion-transmitted infections (RedeS Study)\u2014protocol for a phase 3 clinical trial"],"prefix":"10.1186","volume":"27","author":[{"given":"Edgardo F. Cartagena","family":"Ayala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lumen Vera","family":"Colon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yesim","family":"Aydinok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bol\u00edvar","family":"Arboleda-Osorio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Bracey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross","family":"Fasano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Yee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravindra","family":"Sarode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abba C.","family":"Zubair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Nizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward L.","family":"Snyder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Treml","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clifford","family":"Takemoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryon","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Pitman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Gniadek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley","family":"Bentow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Corash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Mufti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Benjamin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,26]]},"reference":[{"issue":"1","key":"9808_CR1","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.biologicals.2009.10.019","volume":"38","author":"NA Mufti","year":"2010","unstructured":"Mufti NA, Erickson AC, North AK, Hanson D, Sawyer L, Corash LM, et al. Treatment of whole blood (WB) and red blood cells (RBC) with S-303 inactivates pathogens and retains in vitro quality of stored RBC. Biologicals. 2010;38(1):14\u20139.","journal-title":"Biologicals"},{"issue":"1","key":"9808_CR2","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1159\/000324458","volume":"38","author":"R Henschler","year":"2011","unstructured":"Henschler R, Seifried E, Mufti N. Development of the S-303 pathogen inactivation technology for red blood cell concentrates. Transfus Med Hemother. 2011;38(1):33\u201342.","journal-title":"Transfus Med Hemother"},{"issue":"N\u00b04","key":"9808_CR3","first-page":"308","volume":"23","author":"G Castro","year":"2016","unstructured":"Castro G, Stassinopoulos A. Effective inactivation of T-cells with amustaline\/GSH in human RBC as assessed by fluorescent limiting dilution assays (LDA). Transfus Clin Biol. 2016;23(N\u00b04):308.","journal-title":"Transfus Clin Biol"},{"key":"9808_CR4","volume-title":"Guide to the preparation, use and quality assurance of blood components","author":"European Directorate for the Quality of Medicines and Healthcare (EDQM)","year":"2023","unstructured":"European Directorate for the Quality of Medicines and Healthcare (EDQM). Guide to the preparation, use and quality assurance of blood components. 21st Edition. Strasbourg, France: EDQM; 2023.","edition":"21st Edition"},{"issue":"3","key":"9808_CR5","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/vox.12500","volume":"112","author":"JA Cancelas","year":"2017","unstructured":"Cancelas JA, Gottschall JL, Rugg N, Graminske S, Schott MA, North A, et al. Red blood cell concentrates treated with the amustaline (S-303) pathogen reduction system and stored for 35 days retain post-transfusion viability: results of a two-centre study. Vox Sang. 2017;112(3):210\u20138.","journal-title":"Vox Sang"},{"issue":"4","key":"9808_CR6","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1111\/trf.14528","volume":"58","author":"V Brixner","year":"2018","unstructured":"Brixner V, Kiessling AH, Madlener K, Muller MM, Leibacher J, Dombos S, et al. Red blood cells treated with the amustaline (S-303) pathogen reduction system: a transfusion study in cardiac surgery. Transfusion. 2018;58(4):905\u201316.","journal-title":"Transfusion"},{"issue":"4","key":"9808_CR7","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1111\/bjh.15963","volume":"186","author":"Y Aydinok","year":"2019","unstructured":"Aydinok Y, Piga A, Origa R, Mufti N, Erickson A, North A, et al. Amustaline-glutathione pathogen-reduced red blood cell concentrates for transfusion-dependent thalassaemia. Br J Haematol. 2019;186(4):625\u201336.","journal-title":"Br J Haematol"},{"issue":"S3","key":"9808_CR8","first-page":"9A","volume":"64","author":"ME Sekela","year":"2024","unstructured":"Sekela ME, Snyder E, Welsby IJ, Toyoda Y, Sodha NR, Beaver TM, et al. Acute kidney injury to evaluate amustaline\/glutathione pathogen reduced red cells in cardiac surgery: outcomes of the ReCePI Phase III Clinical Trial (AABB Annual Meeting oral abstract PL1-SN-25). Transfusion. 2024;64(S3):9A.","journal-title":"Transfusion"},{"issue":"11","key":"9808_CR9","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1111\/j.1537-2995.2005.00583.x","volume":"45","author":"RJ Benjamin","year":"2005","unstructured":"Benjamin RJ, McCullough J, Mintz PD, Snyder E, Spotnitz WD, Rizzo RJ, et al. Therapeutic efficacy and safety of red blood cells treated with a chemical process (S-303) for pathogen inactivation: a Phase III clinical trial in cardiac surgery patients. Transfusion. 2005;45(11):1739\u201349.","journal-title":"Transfusion"},{"issue":"10","key":"9808_CR10","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1111\/trf.15965","volume":"60","author":"C Geisen","year":"2020","unstructured":"Geisen C, North A, Becker L, Brixner V, von Goetz M, Corash L, et al. Prevalence of natural and acquired antibodies to amustaline\/glutathione pathogen reduced red blood cells. Transfusion. 2020;60(10):2389\u201398.","journal-title":"Transfusion"},{"issue":"2","key":"9808_CR11","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1111\/trf.18117","volume":"65","author":"C Karim","year":"2025","unstructured":"Karim C, Panigrahi A, Pearl RG, Sodha NR, Beaver TM, Pelletier JPR, et al. Characterizing the antibody response to amustaline\/glutathione pathogen-reduced red blood cells. Transfusion. 2025;65(2):344\u201353.","journal-title":"Transfusion"},{"issue":"1","key":"9808_CR12","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/j.1751-2824.2012.01594.x","volume":"7","author":"G Garratty","year":"2012","unstructured":"Garratty G. What is a clinically significant antibody? ISBT Sci Ser. 2012;7(1):54\u20137.","journal-title":"ISBT Sci Ser"},{"key":"9808_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e7586","volume":"346","author":"AW Chan","year":"2013","unstructured":"Chan AW, Tetzlaff JM, G\u00f8tzsche PC, Altman DG, Mann H, Berlin JA, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346:e7586.","journal-title":"BMJ"},{"issue":"13","key":"9808_CR14","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1182\/blood.2019000773","volume":"134","author":"NH Roubinian","year":"2019","unstructured":"Roubinian NH, Plimier C, Woo JP, Lee C, Bruhn R, Liu VX, et al. Effect of donor, component, and recipient characteristics on hemoglobin increments following red blood cell transfusion. Blood. 2019;134(13):1003\u201313.","journal-title":"Blood"},{"issue":"6","key":"9808_CR15","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1046\/j.1537-2995.1997.37697335150.x","volume":"37","author":"JI Elizalde","year":"1997","unstructured":"Elizalde JI, Clemente J, Mar\u00edn JL, Pan\u00e9s J, Arag\u00f3n B, Mas A, et al. Early changes in hemoglobin and hematocrit levels after packed red cell transfusion in patients with acute anemia. Transfusion. 1997;37(6):573\u20136.","journal-title":"Transfusion"},{"key":"9808_CR16","doi-asserted-by":"crossref","unstructured":"Roth A, Mercier A, Lepers C, Hoy D, Duituturaga S, Benyon E, et al. Concurrent outbreaks of dengue, chikungunya and Zika virus infections - an unprecedented epidemic wave of mosquito-borne viruses in the Pacific 2012\u20132014. Euro Surveill. 2014;19(41).","DOI":"10.2807\/1560-7917.ES2014.19.41.20929"},{"issue":"7","key":"9808_CR17","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1111\/trf.13677","volume":"56","author":"MC Lanteri","year":"2016","unstructured":"Lanteri MC, Kleinman SH, Glynn SA, Musso D, Keith Hoots W, Custer BS, et al. Zika virus: a new threat to the safety of the blood supply with worldwide impact and implications. Transfusion. 2016;56(7):1907\u201314.","journal-title":"Transfusion"},{"issue":"7","key":"9808_CR18","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1111\/trf.13681","volume":"56","author":"ML Barjas-Castro","year":"2016","unstructured":"Barjas-Castro ML, Angerami RN, Cunha MS, Suzuki A, Nogueira JS, Rocco IM, et al. Probable transfusion-transmitted Zika virus in Brazil. Transfusion. 2016;56(7):1684\u20138.","journal-title":"Transfusion"},{"key":"9808_CR19","doi-asserted-by":"crossref","unstructured":"Musso D, Nhan T, Robin E, Roche C, Bierlaire D, Zisou K, et al. Potential for Zika virus transmission through blood transfusion demonstrated during an outbreak in French Polynesia, November 2013 to February 2014. Euro Surveill. 2014;19(14).","DOI":"10.2807\/1560-7917.ES2014.19.14.20761"},{"issue":"11","key":"9808_CR20","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1056\/NEJMc1607262","volume":"375","author":"IJ Motta","year":"2016","unstructured":"Motta IJ, Spencer BR, Cordeiro da Silva SG, Arruda MB, Dobbin JA, Gonzaga YB, et al. Evidence for transmission of Zika virus by platelet transfusion. N Engl J Med. 2016;375(11):1101\u20133.","journal-title":"N Engl J Med"},{"issue":"10","key":"9808_CR21","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1056\/NEJMoa1600651","volume":"374","author":"J Mlakar","year":"2016","unstructured":"Mlakar J, Korva M, Tul N, Popovi\u0107 M, Polj\u0161ak-Prijatelj M, Mraz J, et al. Zika virus associated with microcephaly. N Engl J Med. 2016;374(10):951\u20138.","journal-title":"N Engl J Med"},{"issue":"5","key":"9808_CR22","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.stem.2016.02.016","volume":"18","author":"H Tang","year":"2016","unstructured":"Tang H, Hammack C, Ogden SC, Wen Z, Qian X, Li Y, et al. Zika virus infects human cortical neural progenitors and attenuates their growth. Cell Stem Cell. 2016;18(5):587\u201390.","journal-title":"Cell Stem Cell"},{"issue":"10027","key":"9808_CR23","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1016\/S0140-6736(16)00562-6","volume":"387","author":"VM Cao-Lormeau","year":"2016","unstructured":"Cao-Lormeau VM, Blake A, Mons S, Last\u00e8re S, Roche C, Vanhomwegen J, et al. Guillain-Barr\u00e9 Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. Lancet. 2016;387(10027):1531\u20139.","journal-title":"Lancet"},{"issue":"7","key":"9808_CR24","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1111\/trf.13673","volume":"56","author":"MJ Kuehnert","year":"2016","unstructured":"Kuehnert MJ, Epstein JS. Assuring blood safety and availability: Zika virus, the latest emerging infectious disease battlefront. Transfusion. 2016;56(7):1669\u201372.","journal-title":"Transfusion"},{"issue":"Suppl. 1","key":"9808_CR25","first-page":"64","volume":"112","author":"D Musso","year":"2017","unstructured":"Musso D, Santa Maria F, Laughhunn A, Lanteri M, Stassinopoulos A, Aubry M. Pathogen inactivation of Zika, dengue and chikungunya viruses in all blood components. Vox Sang. 2017;112(Suppl. 1):64.","journal-title":"Vox Sang"},{"issue":"4","key":"9808_CR26","first-page":"267","volume":"20","author":"\u00c1 Gim\u00e9nez-Richarte","year":"2022","unstructured":"Gim\u00e9nez-Richarte \u00c1, de Salazar MO, Arbona C, Gim\u00e9nez-Richarte MP, Collado M, Fern\u00e1ndez PL, et al. Prevalence of chikungunya, dengue and Zika viruses in blood donors: a systematic literature review and meta-analysis. Blood Transfus. 2022;20(4):267\u201380.","journal-title":"Blood Transfus"},{"key":"9808_CR27","doi-asserted-by":"crossref","unstructured":"Gim\u00e9nez-Richarte \u00c1, Ortiz de Salazar MI, Gim\u00e9nez-Richarte MP, Larrea L, Arbona C, Marco P, et al. Pathogen inactivation methods to prevent transfusion-transmissible arboviruses: a systematic review and meta-analysis. Trop Med Int Health. 2023;28(4):262\u201374.","DOI":"10.1111\/tmi.13863"},{"issue":"2","key":"9808_CR28","first-page":"95","volume":"14","author":"G Marano","year":"2016","unstructured":"Marano G, Pupella S, Vaglio S, Liumbruno GM, Grazzini G. Zika virus and the never-ending story of emerging pathogens and transfusion medicine. Blood Transfus. 2016;14(2):95\u2013100.","journal-title":"Blood Transfus"},{"issue":"10","key":"9808_CR29","doi-asserted-by":"publisher","first-page":"3164","DOI":"10.1111\/trf.15484","volume":"59","author":"P Saa","year":"2019","unstructured":"Saa P, Chiu C, Grimm K, Yu G, Benjamin RJ, Corash L, et al. Acute Zika virus infection in an asymptomatic blood donor at the onset of the Puerto Rico epidemic. Transfusion. 2019;59(10):3164\u201370.","journal-title":"Transfusion"},{"key":"9808_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens12070911","author":"M Cardoso","year":"2023","unstructured":"Cardoso M, Ragan I, Hartson L, Goodrich RP. Emerging pathogen threats in transfusion medicine: improving safety and confidence with pathogen reduction technologies. Pathogens. 2023. https:\/\/doi.org\/10.3390\/pathogens12070911.","journal-title":"Pathogens"},{"issue":"11","key":"9808_CR31","doi-asserted-by":"publisher","first-page":"2760","DOI":"10.1111\/trf.15986","volume":"60","author":"MB Pagano","year":"2020","unstructured":"Pagano MB, Rajbhandary S, Nunes E, Cohn CS. Transfusion services operations during the COVID-19 pandemic: results from AABB survey. Transfusion. 2020;60(11):2760\u20132.","journal-title":"Transfusion"},{"issue":"12","key":"9808_CR32","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.1111\/trf.13259","volume":"55","author":"S Kleinman","year":"2015","unstructured":"Kleinman S, Stassinopoulos A. Risks associated with red blood cell transfusions: potential benefits from application of pathogen inactivation. Transfusion. 2015;55(12):2983\u20133000.","journal-title":"Transfusion"},{"issue":"11","key":"9808_CR33","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1111\/j.1537-2995.2009.02322.x","volume":"49","author":"SH Kleinman","year":"2009","unstructured":"Kleinman SH, Lelie N, Busch MP. Infectivity of Human immunodeficiency virus-1, Hepatitis C virus, and Hepatitis B virus and risk of transmission by transfusion. Transfusion. 2009;49(11):2454\u201389.","journal-title":"Transfusion"},{"issue":"12","key":"9808_CR34","doi-asserted-by":"publisher","first-page":"2573","DOI":"10.1111\/j.1537-2995.2011.03308.x","volume":"51","author":"MR Jacobs","year":"2011","unstructured":"Jacobs MR, Smith D, Heaton WA, Zantek ND, Good CE, Group PGDS. Detection of bacterial contamination in prestorage culture-negative apheresis platelets on day of issue with the Pan Genera Detection test. Transfusion. 2011;51(12):2573\u201382.","journal-title":"Transfusion"},{"issue":"5","key":"9808_CR35","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1586\/ehm.11.53","volume":"4","author":"L Corash","year":"2011","unstructured":"Corash L. Bacterial contamination of platelet components: potential solutions to prevent transfusion-related sepsis. Expert Rev Hematol. 2011;4(5):509\u201325.","journal-title":"Expert Rev Hematol"},{"issue":"4","key":"9808_CR36","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1182\/blood-2015-07-655944","volume":"127","author":"H Hong","year":"2016","unstructured":"Hong H, Xiao W, Lazarus HM, Good CE, Maitta RW, Jacobs MR. Detection of septic transfusion reactions to platelet transfusions by active and passive surveillance. Blood. 2016;127(4):496\u2013502.","journal-title":"Blood"},{"issue":"1","key":"9808_CR37","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s00277-009-0762-2","volume":"89","author":"G Walther-Wenke","year":"2010","unstructured":"Walther-Wenke G, Schrezenmeier H, Deitenbeck R, Geis G, Burkhart J, Hochsmann B, et al. Screening of platelet concentrates for bacterial contamination: spectrum of bacteria detected, proportion of transfused units, and clinical follow-up. Ann Hematol. 2010;89(1):83\u201391.","journal-title":"Ann Hematol"},{"issue":"3","key":"9808_CR38","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1182\/blood-2015-01-620872","volume":"126","author":"I Kopolovic","year":"2015","unstructured":"Kopolovic I, Ostro J, Tsubota H, Lin Y, Cserti-Gazdewich CM, Messner HA, et al. A systematic review of transfusion-associated graft-versus-host disease. Blood. 2015;126(3):406\u201314.","journal-title":"Blood"},{"issue":"7","key":"9808_CR39","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1111\/j.1537-2995.2008.01771.x","volume":"48","author":"H Mohammed","year":"2008","unstructured":"Mohammed H, Linnen JM, Mu\u00f1oz-Jord\u00e1n JL, Tomashek K, Foster G, Broulik AS, et al. Dengue virus in blood donations, Puerto Rico, 2005. Transfusion. 2008;48(7):1348\u201354.","journal-title":"Transfusion"},{"issue":"8","key":"9808_CR40","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1111\/j.1537-2995.2011.03529.x","volume":"52","author":"LR Petersen","year":"2012","unstructured":"Petersen LR, Tomashek KM, Biggerstaff BJ. Estimated prevalence of dengue viremia in Puerto Rican blood donations, 1995 through 2010. Transfusion. 2012;52(8):1647\u201351.","journal-title":"Transfusion"},{"issue":"1","key":"9808_CR41","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1186\/s13063-023-07831-x","volume":"24","author":"EL Snyder","year":"2023","unstructured":"Snyder EL, Sekela ME, Welsby IJ, Toyoda Y, Alsammak M, Sodha NR, et al. Evaluation of the efficacy and safety of amustaline\/glutathione pathogen-reduced RBCs in complex cardiac surgery: the Red Cell Pathogen Inactivation (ReCePI) study-protocol for a phase 3, randomized, controlled trial. Trials. 2023;24(1):799.","journal-title":"Trials"},{"issue":"6","key":"9808_CR42","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1111\/trf.14610","volume":"58","author":"MEM Yee","year":"2018","unstructured":"Yee MEM, Josephson CD, Winkler AM, Webb J, Luban NLC, Leong T, et al. Hemoglobin A clearance in children with sickle cell anemia on chronic transfusion therapy. Transfusion. 2018;58(6):1363\u201371.","journal-title":"Transfusion"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-026-09808-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-026-09808-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-026-09808-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T23:36:57Z","timestamp":1784590617000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13063-026-09808-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,26]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9808"],"URL":"https:\/\/doi.org\/10.1186\/s13063-026-09808-y","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,26]]},"assertion":[{"value":"28 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The RedeS study (CLI 00126 v9.0) has been approved by the WCG IRB, most recently on 16 January 2025 (IRB Tracking Number: 20162905) and by multiple institutional review boards. Written, informed consent to participate will be obtained from all participants.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained for publication of anonymized patient data at the time of patient consent for enrollment.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"RJB, KL, SB, JPP, TJG, NM, and LC are employees and shareholders of Cerus Corporation, the Sponsor of the study. YA has received research funding from Cerus, Bristol Myers Squibb (BMS), Agios, Novartis, and Sobi, and has served as a consultant for Vertex, BMS, Agios, and Chiesi. All other co-authors are site investigators on the study receive no compensation from the Sponsor and declare no conflicts relating to the study.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"507"}}